KYMR Stock Analysis: Kymera Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.394m USD | 12M Return: 162% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 95.6M
Qual. Beats: 1
Rev. Trend: -44.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs that selectively degrade disease-causing proteins by harnessing the bodys natural protein degradation system, an approach referred to as targeted protein degradation. Its pipeline includes KT-621, an oral STAT6 degrader in Phase 2b trials for immune-mediated conditions including atopic dermatitis, asthma, and COPD; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases; the IRAK4 program (KT-485/SAR447971) in Phase II for immunology and inflammation indications; and a CDK2 program with potential applications in oncology, including breast cancer. As a clinical-stage biotech, Kymera has no approved products on the market and depends on capital markets and partnerships to fund development. The company has a strategic alliance with Sanofi S.A. for IRAK4-directed candidates outside the oncology and immuno-oncology fields, a typical structure in which large pharmaceutical companies license or co-develop assets originated by smaller biotechs. Kymera was incorporated in 2015, is headquartered in Watertown, Massachusetts, and trades on NASDAQ as a mid-cap biotechnology stock following its 2020 IPO.
- KT-621 STAT6 degrader Phase 2b atopic dermatitis results
- Sanofi IRAK4 alliance milestone payments and royalties
- Cash burn and dilution risk from pipeline expansion
| Net Income: -315.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 11.51 > 1.0 |
| NWC/Revenue: 1.19k% < 20% (prev 750.6%; Δ 444.0% < -1%) |
| CFO/TA -0.15 > 3% & CFO -242.6m > Net Income -315.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.5m) vs 12m ago 21.69% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.98% > 50% (prev 6.41%; Δ -2.43% > 0%) |
| Interest Coverage Ratio: -937.6 > 6 (EBIT TTM -315.0m / Interest Expense TTM 336k) |
| A: 0.37 (Total Current Assets 677.4m - Total Current Liabilities 62.6m) / Total Assets 1.67b |
| B: -0.68 (Retained Earnings -1.14b / Total Assets 1.67b) |
| C: -0.24 (EBIT TTM -315.0m / Avg Total Assets 1.29b) |
| D: 11.90 (Book Value of Equity 1.54b / Total Liabilities 129.4m) |
| Altman-Z'' = 11.06 = AAA |
As of July 07, 2026, the stock is trading at USD 114.76 with a total of 611,211 shares traded. Over the past week, the price has changed by +6.14%, over one month by +55.19%, over three months by +34.58% and over the past year by +161.95%.
Current recommended Stop Loss: 106.50 (which is 7.2% or 1.2 ATR below the current price).
Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.
- StrongBuy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 123.8 | 7.8% |
P/S = 182.4892
P/B = 6.1013
Revenue TTM = 51.5m USD
EBIT TTM = -315.0m USD
EBITDA TTM = -306.1m USD
Long Term Debt = 66.7m USD (estimated: total debt 80.5m - short term 13.7m)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 80.5m USD (from shortLongTermDebtTotal, last quarter) (leases 80.5m already included)
Net Debt = -570.5m USD (calculated: Debt 80.5m - CCE 650.9m)
Enterprise Value = 8.82b USD (9.39b + Debt 80.5m - CCE 650.9m)
Interest Coverage Ratio = -937.6 (Ebit TTM -315.0m / Interest Expense TTM 336k)
EV/FCF = -36.16x (Enterprise Value 8.82b / FCF TTM -244.0m)
FCF Yield = -2.77% (FCF TTM -244.0m / Enterprise Value 8.82b)
FCF Margin = -474.1% (FCF TTM -244.0m / Revenue TTM 51.5m)
Net Margin = -612.2% (Net Income TTM -315.1m / Revenue TTM 51.5m)
Gross Margin = unknown ((Revenue TTM 51.5m - Cost of Revenue TTM 2.02m) / Revenue TTM)
Tobins Q-Ratio = 5.29 (Enterprise Value 8.82b / Total Assets 1.67b)
Interest Expense / Debt = 0.42% (Interest Expense 336k / Debt 80.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -248.9m (EBIT -315.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.81 (Total Current Assets 677.4m / Total Current Liabilities 62.6m)
Debt / Equity = 0.05 (Debt 80.5m / totalStockholderEquity, last quarter 1.54b)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -570.5m / EBITDA -306.1m)
Debt / FCF = 2.34 (negative FCF - burning cash) (Net Debt -570.5m / FCF TTM -244.0m)
Total Stockholder Equity = 1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = -24.35% (Net Income -315.1m / Total Assets 1.67b)
RoE = -25.02% (Net Income TTM -315.1m / Total Stockholder Equity 1.26b)
RoCE = -23.76% (EBIT -315.0m / Capital Employed (Equity 1.26b + L.T.Debt 66.7m))
RoIC = -15.39% (negative operating profit) (NOPAT -248.9m / Invested Capital 1.62b)
WACC = 11.17% (E(9.39b)/V(9.47b) * Re(11.26%) + D(80.5m)/V(9.47b) * Rd(0.42%) * (1-Tc(0.21)))
Discount Rate = 11.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 25.49%
[DCF] Fair Price = unknown (Cash Flow -244.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.19 | # QB: 1
Revenue Correlation: -44.75 | Revenue CAGR: -13.62% | SUE: 2.20 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.74 | Chg30d=+1.69% | Revisions=+61% | Analysts=20
EPS next Quarter (2026-09-30): EPS=-1.03 | Chg30d=-0.03% | Revisions=-39% | Analysts=19
EPS current Year (2026-12-31): EPS=-3.52 | Chg30d=+1.17% | Revisions=+45% | GrowthEPS=+4.7% | GrowthRev=+115.4%
EPS next Year (2027-12-31): EPS=-4.35 | Chg30d=+0.56% | Revisions=-21% | GrowthEPS=-23.6% | GrowthRev=-51.4%
[Analyst] Revisions Ratio: +14% (up=36, down=27)